Extended-release ranolazine: critical evaluation of its use in stable angina.

Loading...
Thumbnail Image

Date

2011

Journal Title

Journal ISSN

Volume Title

Repository Usage Stats

156
views
143
downloads

Citation Stats

Abstract

Coronary heart disease is the major cause of morbidity and mortality throughout the world, and is responsible for approximately one of every six deaths in the US. Angina pectoris is a clinical syndrome characterized by discomfort, typically in the chest, neck, chin, or left arm, induced by physical exertion, emotional stress, or cold, and relieved by rest or nitroglycerin. The main goals of treatment of stable angina pectoris are to improve quality of life by reducing the severity and/or frequency of symptoms, to increase functional capacity, and to improve prognosis. Ranolazine is a recently developed antianginal with unique methods of action. In this paper, we review the pharmacology of ranolazine, clinical trials supporting its approval for clinical use, and studies of its quality of life benefits. We conclude that ranolazine has been shown to be a reasonable and safe option for patients who have refractory ischemic symptoms despite the use of standard medications (for example, nitrates, beta-adrenergic receptor antagonists, and calcium channel antagonists) for treatment of anginal symptoms, and also provides a modestly improved quality of life.

Department

Description

Provenance

Citation

Published Version (Please cite this version)

10.2147/VHRM.S15560

Publication Info

Truffa, Adriano Am, L Kristin Newby and Chiara Melloni (2011). Extended-release ranolazine: critical evaluation of its use in stable angina. Vasc Health Risk Manag, 7. pp. 535–539. 10.2147/VHRM.S15560 Retrieved from https://hdl.handle.net/10161/12500.

This is constructed from limited available data and may be imprecise. To cite this article, please review & use the official citation provided by the journal.


Unless otherwise indicated, scholarly articles published by Duke faculty members are made available here with a CC-BY-NC (Creative Commons Attribution Non-Commercial) license, as enabled by the Duke Open Access Policy. If you wish to use the materials in ways not already permitted under CC-BY-NC, please consult the copyright owner. Other materials are made available here through the author’s grant of a non-exclusive license to make their work openly accessible.